Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Show me how to use this page

Ardelyx Inc. Stock

Price
Target price
€7.40

€7.40

-2.140%
-0.162
-2.140%
€11.00
 
08:03 / Tradegate WKN: A116X0 / Name: Ardelyx / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
Buy
None
Sell
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Ardelyx Inc. in the next few years
Wizard

Ardelyx Inc. Stock

A loss of -2.140% shows a downward development for Ardelyx Inc..
The community is currently still undecided about Ardelyx Inc. with 2 Buy predictions and 0 Sell predictions.
As a result the target price of 11 € shows a positive potential of 48.73% compared to the current price of 7.4 € for Ardelyx Inc..
For the coming years our community has positive and negative things to say abot the Ardelyx Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Unique positioning" there were negative voices in the community.

Ardelyx, Inc. is a biopharmaceutical company that focuses on the research, development, and commercialization of innovative medicines aimed at treating kidney and cardiovascular diseases. The company uses a unique approach to drug discovery, developing therapeutics that target ion channels and transporters, which play a critical role in regulating activities in the body. Ardelyx's lead product candidate, tenapanor, is being studied for the treatment of conditions such as hyperphosphatemia in patients with chronic kidney disease, irritable bowel syndrome with constipation, and diverticulosis. The company is listed on the NASDAQ exchange under the ticker symbol ARDX.

Pros and Cons of Ardelyx Inc. in the next few years

Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Cons
?
C******** o* t** e**********
?
B****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Your Opinion
Legal notice

Performance of Ardelyx Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Ardelyx Inc. -2.140% 19.664% 14.204% 98.895% 30.761% 36.180% -
Evolus Inc -1.650% 2.542% 0.000% 47.561% 33.702% 64.626% -
Salarius Pharmaceuticals Inc. 2.480% -12.174% -6.047% -77.430% -27.207% -98.343% -99.993%
Brainstorm Cell 0.720% -5.986% -36.372% -87.204% 48.922% -86.913% -
Register To Post

News

3 mid-caps under $20 that Wall Street loves: https://www.marketbeat.com/logos/articles/med_20240122191242_3-mid-caps-under-20-that-wall-street-loves.jpg
3 mid-caps under $20 that Wall Street loves

Just three trading weeks into the new year, a half dozen U.S. mid- or large-cap stocks are already up 20% or more.

Picking up where it left off last year, artificial intelligence (AI) data center

MarketBeat 
0 23.01.24